Santarus CEO Hosts Analyst Day (Transcript)
Apr 11 2013, 18:29 | about: SNTS
For acute HAE, what’s the reasonable forecast for Ruconest may be somewhere in the $100,000,000 range could it be a little bit better, yes it could be a little better, it could be little worse, yes it could be a little worse. But we are thinking that’s a reasonable range for acute pancreatitis. One of the things that we really do believe is while “the safety of plasma-derived product is not an issue right now, it’s because the patients don’t have a safer option. Once Ruconest is available they’ll have a safer option, it is a recombinant product and as both Mark and Wendell talked about, it’s a very affective product. We’re delivering 50 units per kilogram C1 esterase inhibitor.
And if you look at the other products Berinert delivering 20 units per kilograms and Cinryze is delivering about 13 units per kilograms. The reason we can deliver 50 units per kilogram has to do with the cost of goods and effective recombinant products. So we’re getting lot of product in there that’s why we think we’re getting very good efficacy.
One of the things that’s interesting in this marketplace is because of all the other launches, what we hear from patients are, they are very open to trying other products. Many patients already have tried two or three different products. So, they continue to look for products is given good efficacy and we think we have a nice opportunity here to get the product to use.
RUCONEST we expect to file the BLA here shortly.